Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | SOD3 | P08294 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15882090 | 0.84 | PDCD1 (0.45) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL7011116 | 0.83 | PDCD1 (0.42) | PDCD1CD274TLR9TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL29721354 | 0.83 | PDCD1 (0.44) | PDCD1CD274TLR9TLR8TLR7 | |
| SCHEMBL2752951 | 0.78 | CXCR4 (0.42) | PDCD1CD274MGLLCXCR4 | |
| SCHEMBL107873 | 0.77 | PDCD1 (0.50) | PDCD1CD274TLR9TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL2339479 | 0.76 | CXCR4 (0.41) | PDCD1CD274CXCR4 | |
| SCHEMBL15882118 | 0.75 | CXCR4 (0.46) | PDCD1CD274CXCR4 | |
| SCHEMBL19741695 | 0.74 | PDCD1 (0.35) | PDCD1CD274MGLLCXCR4 | |
| SCHEMBL13455831 | 0.73 | WDR5 (0.46) | — | |
| SCHEMBL15933517 | 0.73 | PDCD1 (0.43) | PDCD1CD274TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| WO-2017007755-A1 | HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| EP-2424867-B1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513248-B2 | 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2424867-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | PDCD1 3029/4885CD274 3302/4885TLR9 2521/4885 |
| US-20120172366-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | PDCD1 4494/4885CD274 3515/4885TLR9 725/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | PDCD1 545/4885CD274 724/4885TLR9 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.